PT2328931E - Anticorpos selectivos anti-hepcidina-25 e utilizações dos mesmos - Google Patents

Anticorpos selectivos anti-hepcidina-25 e utilizações dos mesmos Download PDF

Info

Publication number
PT2328931E
PT2328931E PT97909089T PT09790908T PT2328931E PT 2328931 E PT2328931 E PT 2328931E PT 97909089 T PT97909089 T PT 97909089T PT 09790908 T PT09790908 T PT 09790908T PT 2328931 E PT2328931 E PT 2328931E
Authority
PT
Portugal
Prior art keywords
ser
thr
seq
gly
leu
Prior art date
Application number
PT97909089T
Other languages
English (en)
Portuguese (pt)
Inventor
Peng Luan
Ying Tang
Derrick Ryan Witcher
Donmienne Doen Mun Leung
Pia Pauliina Yachi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2328931E publication Critical patent/PT2328931E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT97909089T 2008-08-06 2009-07-29 Anticorpos selectivos anti-hepcidina-25 e utilizações dos mesmos PT2328931E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8655708P 2008-08-06 2008-08-06

Publications (1)

Publication Number Publication Date
PT2328931E true PT2328931E (pt) 2013-11-07

Family

ID=41165490

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97909089T PT2328931E (pt) 2008-08-06 2009-07-29 Anticorpos selectivos anti-hepcidina-25 e utilizações dos mesmos

Country Status (19)

Country Link
US (1) US8609817B2 (https=)
EP (1) EP2328931B1 (https=)
JP (1) JP5730200B2 (https=)
KR (1) KR101462307B1 (https=)
CN (1) CN102112489B (https=)
AU (1) AU2009279865B2 (https=)
BR (1) BRPI0916624A2 (https=)
CA (1) CA2733497C (https=)
DK (1) DK2328931T3 (https=)
EA (1) EA201170312A1 (https=)
ES (1) ES2432018T3 (https=)
IL (1) IL210643A (https=)
MX (1) MX2011001363A (https=)
NZ (1) NZ590863A (https=)
PL (1) PL2328931T3 (https=)
PT (1) PT2328931E (https=)
UA (1) UA103032C2 (https=)
WO (1) WO2010017070A1 (https=)
ZA (1) ZA201100261B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608683B1 (en) * 2003-04-01 2011-11-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies directed against hepatitis c virus e1e2 complex and pharmaceutical compositions
PE20091261A1 (es) * 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
NZ606584A (en) 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
AU2012350654C1 (en) 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) * 2012-10-26 2014-05-01 Claresa Levetan Generation of new pancreatic beta cells
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
US9657098B2 (en) * 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
WO2015051320A2 (en) * 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
WO2016027469A1 (ja) * 2014-08-21 2016-02-25 国立大学法人旭川医科大学 ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
AU2015321462B2 (en) * 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
EP3268027B1 (en) 2015-03-13 2022-11-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Hepcidin antagonists for use in the treatment of inflammation
CA3038894A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
EP3559039A1 (en) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
CN109948371B (zh) * 2019-03-07 2021-06-25 深圳市智税链科技有限公司 为区块链节点发放身份证书的方法及相关装置
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
EP4279924A4 (en) * 2021-01-18 2024-06-26 FUJIFILM Corporation ADSORPTION INHIBITOR FOR HEPCIDIN, ADSORPTION INHIBITOR METHOD, REFERENCE STANDARD, REAGENT, KIT AND MEASUREMENT METHODS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478145T1 (de) 1999-06-02 2010-09-15 Genentech Inc Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
JP4944360B2 (ja) 2001-05-25 2012-05-30 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
CA2506668C (en) 2002-11-19 2014-08-19 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
JP2007518062A (ja) 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
AU2006223374B2 (en) * 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2009044284A1 (en) 2007-10-02 2009-04-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies specific for human hepcidin
PE20091261A1 (es) * 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use

Also Published As

Publication number Publication date
JP5730200B2 (ja) 2015-06-03
AU2009279865A1 (en) 2010-02-11
ZA201100261B (en) 2012-06-27
MX2011001363A (es) 2011-04-26
EP2328931A1 (en) 2011-06-08
IL210643A0 (en) 2011-03-31
KR20110031963A (ko) 2011-03-29
IL210643A (en) 2015-09-24
HK1156326A1 (en) 2012-06-08
DK2328931T3 (da) 2013-09-30
CN102112489B (zh) 2014-05-14
BRPI0916624A2 (pt) 2015-12-01
KR101462307B1 (ko) 2014-11-17
WO2010017070A1 (en) 2010-02-11
PL2328931T3 (pl) 2014-01-31
JP2011530514A (ja) 2011-12-22
UA103032C2 (uk) 2013-09-10
US20110189190A1 (en) 2011-08-04
CA2733497C (en) 2015-06-02
NZ590863A (en) 2012-10-26
CA2733497A1 (en) 2010-02-11
CN102112489A (zh) 2011-06-29
EA201170312A1 (ru) 2012-03-30
AU2009279865B2 (en) 2013-10-10
ES2432018T3 (es) 2013-11-29
EP2328931B1 (en) 2013-08-14
US8609817B2 (en) 2013-12-17

Similar Documents

Publication Publication Date Title
ES2432018T3 (es) Anticuerpos selectivos anti-hepcidina-25 y usos de los mismos
JP6948415B2 (ja) 抗ｇｐ７３モノクローナル抗体およびそれを得る方法
CN112250763B (zh) 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途
AU2020245031B2 (en) Antibodies to pyroglutamate amyloid-β and uses thereof
ES2661516T3 (es) Biomarcadores
JP7478708B2 (ja) 胃癌の検出および治療のための組成物および方法
US11866487B2 (en) Filamin A binding proteins and uses thereof
JP2025020209A (ja) インターロイキン－１９を標的とする化合物および方法
WO2015048929A1 (en) Biomarkers for breast cancer
US20250042976A1 (en) Monoclonal antibodies specific for sars-cov-2 rbd
CN101432308A (zh) Fas结合抗体
JP2016510870A (ja) 補体因子ｈ関連タンパク質１検出のための剤、キットおよび方法
KR20210073785A (ko) 호산구 유래 신경독과 특이적으로 결합하는 단일클론항체 및 이의 용도
US12590977B2 (en) Anti-ceruloplasmin antibodies and uses thereof
HK1156326B (en) Anti-hepcidin-25 selective antibodies and uses thereof